The prognosis of patients with HCC is partly dependent on the type of mutations present in HCC, with patients bearing β-catenin (CTNNB1) mutations having a better prognosis than those bearing p53 (TP53) mutations [41]. This evidence concerns the gene TP53 and hepatocellular carcinoma.